Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Feb;45(2):621-3.
doi: 10.1128/AAC.45.2.621-623.2001.

Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis

R Patel  1 , M S Rouse, K E Piper, J M Steckelberg
Affiliations

Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis

R Patel et al. Antimicrob Agents Chemother. 2001 Feb.

Abstract

We compared the activities of linezolid (25 mg/kg of body weight, administered intraperitoneally every 8 h) and of vancomycin (25 mg/kg of body weight, administered intraperitoneally every 8 h) in a rat model of vanA vancomycin-resistant Enterococcus faecium experimental endocarditis. Results were expressed as median log(10) CFU per gram of vegetation after 3 days of treatment. The median log(10) CFU per gram of vegetation was 10.1 among 7 untreated control animals, 10.2 among 9 vancomycin-treated animals, and 7.9 among 10 linezolid-treated animals. Linezolid treatment was more active (P < 0.05) than vancomycin treatment or no treatment.

PubMed Disclaimer

References

    1. Chien J, Kucia M, Salata R. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin Infect Dis. 2000;30:146–151. - PubMed
    1. Chow J W, Donahedian S M, Zervos M J. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis. 1997;24:90–91. - PubMed
    1. Ford C W, Hamel J C, Wilson D M, Moerman J K, Stapert D, Yancey R J, Jr, Hutchinson D K, Barbachyn M R, Brickner S J. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother. 1996;40:1508–1513. - PMC - PubMed
    1. Hellinger W C, Rouse M S, Rabadan P M, Henry N K, Steckelberg J M, Wilson W R. Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci. Antimicrob Agents Chemother. 1992;36:1272–1275. - PMC - PubMed
    1. Matsumura S, Simor A E. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis. 1998;27:1554–1556. - PubMed